ArticleBMC veterinary research2025
Development of two indirect ELISAs using purified recombinant viral proteins to detect myxoma virus-antigen specific antibodies in rabbit sera.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite the use of effective vaccines, myxomatosis remains a blight on European rabbit farms. The causative agent, myxoma virus (MYXV), is endemic in wild populations of leporids on the Iberian Peninsula. The detection of specific anti-MYXV antibodies in rabbit sera provides an essential part of control and epidemiological programs in both wild and domestic rabbits. Currently, the detection of specific antibodies is carried out by indirect (i)ELISA and competitive (c)ELISA, both using complete MYXV as antigen which requires stringent biosecurity controls. In this study, two full-length recombinant (r) viral proteins, rM022 and rM115, were shown to be antigenic and fit for the development of independent iELISAs for the detection of anti-MYXV antibodies in rabbit sera. The two iELISAs were optimized using a panel of 259 sera that had previously been characterized using commercially available iELISAs. The rM022 and rM115 based iELISAs in receiver operating characteristic (ROC) analysis showed areas under curve (AUC) values > 0.9 with specificities of 83.65% (rM022) and 75% (rM115) and sensitivities of 90.97% (rM022) and 96.77% (rM115), respectively. The use of recombinant proteins to detect anti-MYXV antibodies in rabbit sera shows promise as complementary analyses to existing ELISAs and provide valuable additional information regarding the presence of antigen-specific antibodies following vaccination. Furthermore, this study offers significant value by enabling a detailed characterization of viral proteins M022 and M115, particularly in terms of their antigenicity. Understanding the antigenic properties of viral proteins is crucial as it facilitates the development of more effective vaccines and enables accurate assessment of the immune response. This has a major impact on improving protection and monitoring viral infections, providing a solid foundation for the development of new prevention and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.